Pulmonary embolism in a 30 year-old man with chronic hepatitis C during therapy with pegylated interferon-α and ribavirin

被引：0

作者：

Elikowski, Waldemar ^{[1
]}

Malek, Malgorzata ^{[1
]}

Kurosz, Jolanta ^{[2
]}

Bereszynska, Iwona ^{[3
]}

Marszalek, Andrzej ^{[4
]}

Zawilska, Krystyna ^{[5
]}

Mozer-Lisewska, Iwona ^{[4
,6
]}

机构：

[1] Szpital J Strusia, Oddzial Chorob Wewnetrznych, PL-61285 Poznan, Poland

[2] Szpital J Strusia, Pracownia Hemostazy, PL-61285 Poznan, Poland

[3] ZOZ Poznan Stare Miasto, Poradnia Chorob Watroby, Poznan, Poland

[4] Szpital J Strusia, Oddzial Chorob Zakaznych, PL-61285 Poznan, Poland

[5] Szpital J Strusia, Oddzial Chorob Wewnetrznych & Hematol, PL-61285 Poznan, Poland

[6] Uniwersytet Med, Katedra & Klin Chorob Zakaznych, Poznan, Poland

来源：

KARDIOLOGIA POLSKA | 2010年 / 68卷 / 11期

关键词：

pulmonary embolism; interferon-alpha; ribavirin; chronic hepatitis C; VENOUS THROMBOEMBOLISM; CUTANEOUS NECROSIS; PLUS RIBAVIRIN; PATIENT; COMBINATION; INJECTION; FIBROSIS; PROTEIN; VIRUS; RISK;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The authors described a case of a 30 year-old man with chronic hepatitis C (G1,S1) complicated by pulmonary embolism (PE), preceded by symptoms of respiratory system infection, which occurred after 6 months of combination therapy with pegylated interferon-a and ribavirin. Right sided nonbacterial thrombotic endocarditis as a source of segmental/subsegmental PE was found. Hemostatic work up showed increased activated protein C resistance, elevated factor VIII activity and fibrinogen concentration as well as hyperhomocysteinaemia (all these disturbances returned to normal 3-6 months later). The patient's clinical status improved during anticoagulation therapy. Antiviral treatment was not continued as virological response was achieved.

引用

页码：1261 / 1265

页数：5

共 50 条

[41] Combination Therapy with Interferon-α2b, Ribavirin, and Amantadine in Chronic Hepatitis C Nonresponders to Interferon and Ribavirin [J].

Paul J. Thuluvath ;

Hemant Pande ;

Joyce Maygers .

Digestive Diseases and Sciences, 2003, 48 :594-597

[42] Combination therapy with interferon-α2b, ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin [J].

Thuluvath, PJ ;

Pande, H ;

Maygers, J .

DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (03) :594-597

[43] Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy [J].

Joshita, Satoru ;

Shirahata, Kumiko ;

Yazaki, Yoshikazu ;

Okaniwa, Shinji ;

Nakamura, Yoshiyuki ;

Kimura, Takefumi ;

Noami, Sugiko ;

Horigome, Reiko ;

Yagi, Hikaru ;

Ito, Nobuo ;

Yamazaki, Asami ;

Akahane, Yuki ;

Umemura, Takeji ;

Yoshizawa, Kaname ;

Tanaka, Eiji ;

Ota, Masao .

HEPATOLOGY RESEARCH, 2013, 43 (07) :801-807

[44] Liver Function under Interferon/Ribavirin Therapy of Chronic Hepatitis C [J].

Stintzing, S. ;

Schmitt, C. ;

Ocker, M. ;

Ganslmayer, M. ;

Zopf, S. ;

Gahr, S. ;

Hahn, E. G. ;

Herold, C. .

HEPATO-GASTROENTEROLOGY, 2009, 56 (90) :462-465

[45] Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study [J].

Hsieh, Ming-Han ;

Kao, Tzu-Yu ;

Hsieh, Ting-Hui ;

Kao, Chun-Chi ;

Peng, Cheng-Yuan ;

Lai, Hsueh-Chou ;

Chuang, Po-Heng ;

Kao, Jung-Ta .

THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13

[46] Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with the Combined Pegylated Interferon-Ribavirin Therapy [J].

Hamza, Iman ;

Eid, Yara ;

El-Sayed, Mohammad ;

Marzaban, Raghda ;

Abdul-Kareem, Shaimaa .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2016, 36 (09) :527-533

[47] Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan [J].

Kogure, Takayuki ;

Ueno, Yoshiyuki ;

Fukushima, Koji ;

Nagasaki, Futoshi ;

Kondo, Yasuteru ;

Inoue, Jun ;

Matsuda, Yasunori ;

Kakazu, Eiji ;

Yamamoto, Takeshi ;

Onodera, Hiroyoshi ;

Miyazaki, Yutaka ;

Okamoto, Hiromasa ;

Akahane, Takehiro ;

Kobayashi, Tomoo ;

Mano, Yutaka ;

Iwasaki, Takao ;

Ishii, Motoyasu ;

Shimosegawa, Tooru .

WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (47) :7225-7230

[48] Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C [J].

Kowala-Piaskowska, Arleta ;

Mozer-Lisewska, Iwona ;

Figlerowicz, Magdalena ;

Sluzewski, Wojciech .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (10) :1095-1103

[49] Ribavirin enhances interferon-γ levels in patients with chronic hepatitis C treated with interferon-α [J].

Fang, SH ;

Lai, MY ;

Hwang, LH ;

Yang, PM ;

Chen, PJ ;

Chiang, BL ;

Chen, DS .

JOURNAL OF BIOMEDICAL SCIENCE, 2001, 8 (06) :484-491

[50] Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C [J].

Condat, Bertrand ;

Asselah, Tarik ;

Zanditenas, David ;

Estampes, Bertrande ;

Cohen, Ariel ;

O'Toole, Dermot ;

Bonnet, Joelle ;

Ngo, Yann ;

Marcellin, Patrick ;

Blazquez, Martine .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (03) :287-289

← 1 2 3 4 5 →